Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$9.16M+440.21%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Curran Simpson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 0.93
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -2.82
Financials
Revenue
$9.16M+440.2%Net Income
$-40.74MEBITDA
$-29.75MFree Cash Flow
$38.41MEPS (diluted)
$-0.62Shares Outstanding (diluted)
65.26M+146.5%Operating Expenses
$81.59MCash & Debt
$250.98MReturn of Capital
$0.00Revenue by Segment (annual)
$170.44MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.44M | $-193.88M | $-3.76 |
| 2024 | $83.33M | $-227.10M | $-4.59 |
| 2023 | $90.24M | $-263.49M | $-6.02 |
| 2022 | $112.72M | $-280.32M | $-6.50 |
| 2021 | $470.35M | $127.84M | $3.01 |
| 2020 | $154.57M | $-111.25M | $-2.98 |
| 2019 | $35.23M | $-94.73M | $-2.58 |
| 2018 | $218.50M | $99.94M | $2.73 |
| 2017 | $10.39M | $-73.17M | $-2.45 |
| 2016 | $4.59M | $-62.97M | $-2.38 |
| 2015 | $7.59M | $-22.81M | $-2.49 |
| 2014 | $6.12M | $-4.00M | $-0.30 |
| 2013 | $6.09M | $-5.39M | $-2.04 |
Valuation
RGNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-47.50%Social Signal Score
Mentions (22)
- Newsseekingalpha.com·9d ago·Positive
REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript REGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·16d ago·Neutral
Regenxbio: 2 Major Catalysts Could Change The Investment Case Regenxbio Inc. is Buy-rated, with upcoming ATMOSPHERE and ASCENT readouts and RGX-202 regulatory milestones as key near-term catalysts. RGNX faces a structural revenue headwind from ZOLGENSMA royalty expiration, with new assets like ITVISMA and external funding supporting liquidity. Pivotal wet AMD Phase III data for sura-vec in 4Q26 and an RGX-202 BLA submission in 1Q27 are critical for future valuation.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
REGENXBIO Q3 Earnings Call Highlights REGENXBIO NASDAQ: RGNX is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company's third-quarter earnings call.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript REGENXBIO Inc. (RGNX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates Regenxbio (RGNX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to a loss of $1.2 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md.
View source ↗ - Newszacks.com·18d ago·Neutral
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 214.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsprnewswire.com·19d ago·Neutral
REGENXBIO to Participate in Stifel 2026 Healthcare Conference ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.
View source ↗ - Newsprnewswire.com·24d ago·Neutral
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m.
View source ↗ - Newsmarketbeat.com·32d ago·Neutral
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy REGENXBIO NASDAQ: RGNX outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or wet AMD, during a company event featuring retina specialists and executives.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript
View source ↗ - Newsprnewswire.com·41d ago·Neutral
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.
View source ↗ - Newsprnewswire.com·59d ago·Neutral
…tment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·75d ago·Neutral
REGENXBIO to Participate in Upcoming Investor Conferences ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.
View source ↗ - Newszacks.com·89d ago·Negative
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
View source ↗ - Newsseekingalpha.com·89d ago·Negative
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
View source ↗ - Newsprnewswire.com·89d ago·Neutral
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
View source ↗ - Newsbarrons.com·90d ago·Neutral
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
View source ↗ - Newsreuters.com·90d ago·Negative
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome Regenxbio said on Monday the U.S. Food and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities in five study participants.
View source ↗ - Newsprnewswire.com·90d ago·Neutral
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
View source ↗ - Newsseekingalpha.com·103d ago·Neutral
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.96 per share
Typical surprise -22.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.62 vs $-1.29beat
- Thu, Aug 6$0.43 vs $0.08beat
- Thu, May 14$-1.72 vs $-1.36miss
- Thu, Mar 5$-1.30 vs $-1.01miss
- Thu, Nov 6$-1.20 vs $-1.38beat
- Thu, Aug 7$-1.38 vs $-1.13miss
Estimates and results for RGNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RGNX officers and directors.
- Bought
- $949k
- Sold
- $1.5m
2 trades
9 trades
- Ciongoli Gregory Austinbought
- Ciongoli Gregory Austinbought
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Pakola Stevesold
- Simpson Curransold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Peter Welchhouse · VT00 · disclosed Nov 14, 2019 (6d later)Sell$1,001 - $15,000
- Peter Welchhouse · VT00 · disclosed Nov 14, 2019 (23d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
